quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·3d
PRRelease
Alnylam Pharmaceuticals Inc. logo
Arcturus Therapeutics Holdings Inc. logo
Denali Therapeutics Inc. logo
+1

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

ALNY· Alnylam Pharmaceuticals Inc.ARCT· Arcturus Therapeutics Holdings Inc.DNLI· Denali Therapeutics Inc.SRPT· Sarepta Therapeutics Inc.
Health Care
Original source

Companies

  • ALNY
    Alnylam Pharmaceuticals Inc.
    Health Care
  • ARCT
    Arcturus Therapeutics Holdings Inc.
    Health Care
  • DNLI
    Denali Therapeutics Inc.
    Health Care
  • SRPT
    Sarepta Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 26DNLIUpdateH.C. Wainwright$42.00
  • Mar 18ARCTUpdateB. Riley Securities$22.00
  • Mar 16ALNYUpdateJefferies$330.00
  • Feb 24DNLIUpdateWolfe Research-
  • Jan 28SRPTUpdateBarclays$20.00
  • Jan 28ALNYUpdateBarclays$527.00

Related

  • PR1d
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
  • INSIDER2d
    Amendment: SEC Form 3 filed by new insider Chin Peter Scott
  • SEC2d
    SEC Form DEFA14A filed by Denali Therapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Denali Therapeutics Inc.
  • INSIDER3d
    SEC Form 3 filed by new insider Chin Peter Scott
  • PR7d
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
  • INSIDER16d
    SEC Form 4 filed by Mclaughlin Melissa
  • INSIDER16d
    SEC Form 3 filed by new insider Mclaughlin Melissa
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022